Documentation: Pfizer vaccine production chain // Photo: Pfizer
The importance of the position paper is in its speed in relation to the detection of the new mutation, as well as in the relatively comprehensive examination of the virus directly in front of the vaccine. It is important to note that this is an evaluation because the test was done in a laboratory and not in humans directly. However, the position paper states that “examining the information obtained, together with the knowledge we have about the actions created in the body following the activation of our vaccine, make us assume that the body’s immune system will also be resistant to this mutation.”
However, the researchers note that “there should be concern about the evolution of the corona virus and surveillance should be maintained. Although at present the virus is not resistant to the vaccine.” It is important to note that Pfizer herself along with researchers at the University of Texas tested the vaccine action against the British mutation earlier this month, however then the test was partial and did not include an overall direct response against the British version. In general, both Modern and Astraznica are testing their vaccines against the new British mutation, and will publish their findings later this month as well.
It is important to note that the researchers themselves note that in the future a resistant mutation to the current vaccine may be discovered, and it will be necessary to adapt it to it. However, once a vaccine has been developed, it is easier to adapt it each time to the new mutations that emerge each year. This point is important because there are initial reports from South Africa of an even stronger version of the virus, which raises concerns regarding the development of a vaccine-resistant strain.